GeoVax Labs (NASDAQ:GOVX) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research note published on Friday,Benzinga reports. D. Boral Capital currently has a $18.00 price objective on the stock.

A number of other equities research analysts have also weighed in on the stock. Alliance Global Partners initiated coverage on shares of GeoVax Labs in a report on Monday, November 11th. They set a “buy” rating and a $15.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research note on Friday, November 15th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $14.20.

GeoVax Labs Stock Down 2.1 %

GOVX opened at $1.91 on Friday. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18. The stock’s 50 day moving average price is $2.33 and its 200-day moving average price is $2.74.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to the consensus estimate of $1.84 million. During the same period last year, the company earned ($4.80) EPS. Equities analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current year.

Institutional Investors Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC acquired a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs as of its most recent SEC filing. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.